The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association

Hong, Angela; Lo, Helen.; Lawless, Anna.; Zhou, Deborah.; Bae, Susie; Phillips, Marianne; Maclean, Fiona.; Desai, Jayesh.; Mar, Jasmine.; Lazarakis, Smaro.; Pryor, David; Thompson, Stephen R.

doi:10.1016/j.radonc.2022.10.037

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been demonstrated that delivery of radiotherapy in rare tumours like sarcomas, and thus arguably chordomas, is best done at specialised treatment centres. 58 This an important concept to consider in Australia with a population of only 26.5 million people and an incidence of skull base chordoma of 0.033 per 100,000 population. 59 Extrapolating this to the introduction of proton therapy to the region, there needs to be a robust system of multidisciplinary communication between geographically distant specialists and systematic referrals to a nationally accessible proton centre.…”

Section: The Multidisciplinary Team Approachmentioning

confidence: 99%

“…The study demonstrated that academic centres operating on at least seven patients a year with skull base chordoma had superior outcomes compared to units who operated on fewer patients per year. It has also been demonstrated that delivery of radiotherapy in rare tumours like sarcomas, and thus arguably chordomas, is best done at specialised treatment centres 58 . This an important concept to consider in Australia with a population of only 26.5 million people and an incidence of skull base chordoma of 0.033 per 100,000 population 59 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proton beam therapy for clival chordoma: Optimising rare cancer treatments in Australia

Mathew,

Gorayski,

Candy

et al. 2024

J of Medical Radiation Sci

View full text Add to dashboard Cite

With the anticipated launch of the Australian Bragg Centre for Proton Therapy and Research (ABCPTR) in Adelaide, Australia, proton therapy will become a significant addition to existing cancer treatment options for Australians. The anticipated benefits will be particularly evident in rare cancers such as clival chordomas, a challenging tumour entity due to the anatomical relationship with critical structures, and proven radio‐resistance to conventional radiation therapy. The article synthesises key findings from major studies and evaluates the current evidence supporting various management strategies for clival chordomas. It also considers the influence of institutional volume and multidisciplinary team management on patient outcomes and outlines how high‐quality care can be effectively delivered within the Australian healthcare system, emphasising the potential impact of proton therapy on the treatment paradigm of clival chordomas in Australia.

show abstract

Section: The Multidisciplinary Team Approachmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%